Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 6Lymphoid 6Thoracic 3Myeloid 3Dermatologic 3Gynecologic 2Endocrine 2Other solid neoplasm 1NET 1Gastrointestinal 1

Conditions

Carcinoma, Neuroendocrine 2Small Cell Lung Carcinoma 1Neuroendocrine Tumors 1Carcinoma 1

Interventions

Magnetic Resonance Spectroscopy 17Specimen Handling 13lutetium Lu 177 dotatate 7gallium Ga 68 dotatate 7Cisplatin 7cabozantinib 6pazopanib 5Sorafenib 5Fluorodeoxyglucose F18 5Everolimus 5Etoposide 4romidepsin 3olaparib 3fluorodopa F 18 3cixutumumab 3X-Rays 3Temozolomide 3Sunitinib 3Radiotherapy 3Nivolumab 3Ipilimumab 3Iodine-131 3CTLA-4 Antigen 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3tipifarnib 2belinostat 2aldesleukin 2aflibercept 2Vorinostat 2Trastuzumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × belinostat × Endocrine × Clear all
NCT06406465 2026-06-05

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
60 enrolled
EndocrineNET

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT00926640 2018-10-19

A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
28 enrolled
EndocrineThoracic

Carcinoma, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡